Dextroamphetamine sulfate 7.5 MG Oral Tablet [Zenzedi] — RxCUI 1426253
RxNorm drug concept · Semantic branded drug
RxCUI 1426253
Semantic branded drug · SBD
● Current RxNorm concept 7 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1426253
Official nameDextroamphetamine sulfate 7.5 MG Oral Tablet [Zenzedi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZenzedi 7.5 MG Oral Tablet
FDA products mapped7
Package NDCs mapped7
Reported Medicaid activity (SDUD)192 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Dextroamphetamine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It sounds counterintuitive, but stimulants actually calm things down for many people with ADHD. Dextroamphetamine boosts dopamine and norepinephrine — two brain chemicals involved...
- What exactly does dextroamphetamine do, and why does a stimulant help with ADHD?
- The most common ones are decreased appetite, trouble sleeping, and headache — and decreased appetite is very common, especially early on. Taking doses too late in the day tends to...
- What are the most common side effects I should expect?
🕸️ Concept Web — How Dextroamphetamine sulfate 7.5 MG Oral Tablet [Ze... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Dextroamphetamine sulfate 7.5 MG Oral Tablet [Zenzedi]
RxCUI 1426253 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Dextroamphetamine
3288IN -
Dextroamphetamine sulfate
3287PIN
-
Dextroamphetamine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Zenzedi
1425332BN
-
Zenzedi
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Dextroamphetamine Oral Tablet
371753SCDF -
Dextroamphetamine sulfate Oral Tablet
2647496SCDFP -
Dextroamphetamine Oral Product
1154565SCDG -
Dextroamphetamine Pill
1154566SCDG -
Dextroamphetamine sulfate Oral Product
2662479SCDGP -
Dextroamphetamine sulfate Pill
2661847SCDGP -
Dextroamphetamine Oral Tablet [Zenzedi]
1425334SBDF -
Dextroamphetamine sulfate Oral Tablet [Zenzedi]
2656743SBDFP - +5 more in this family
-
Dextroamphetamine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Dextroamphetamine sulfate 7.5 MG Oral Tablet
1425854SCD -
Dextroamphetamine sulfate 7.5 MG
578547SCDC -
Dextroamphetamine sulfate 7.5 MG [Zenzedi]
1426252SBDC
-
Dextroamphetamine sulfate 7.5 MG Oral Tablet
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Dextroamphetamine sulfate 7.5 MG Oral Tablet
SCD · 1425854 -
Dextroamphetamine sulfate 7.5 MG
SCDC · 578547 -
Dextroamphetamine Oral Tablet
SCDF · 371753 -
Dextroamphetamine sulfate Oral Tablet
SCDFP · 2647496 -
Dextroamphetamine Oral Product
SCDG · 1154565 -
Dextroamphetamine Pill
SCDG · 1154566 -
Dextroamphetamine sulfate Oral Product
SCDGP · 2662479 -
Dextroamphetamine sulfate Pill
SCDGP · 2661847
Brand-Name Concepts
-
Dextroamphetamine sulfate 7.5 MG [Zenzedi]
SBDC · 1426252 -
Dextroamphetamine Oral Tablet [Zenzedi]
SBDF · 1425334 -
Dextroamphetamine sulfate Oral Tablet [Zenzedi]
SBDFP · 2656743 -
Zenzedi Oral Product
SBDG · 1425335 -
Zenzedi Pill
SBDG · 1425336 -
Zenzedi
BN · 1425332
📦 FDA Products & Package NDCs
7 products · 7 package NDCs
7 package NDCs map to RxCUI 1426253 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 24338-0850-03 | 30 TABLET in 1 BOTTLE (24338-850-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-10 |
| 24338-0851-03 | 30 TABLET in 1 BOTTLE (24338-851-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
| 24338-0852-03 | 30 TABLET in 1 BOTTLE (24338-852-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
| 24338-0853-03 | 30 TABLET in 1 BOTTLE (24338-853-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
| 24338-0854-03 | 30 TABLET in 1 BOTTLE (24338-854-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
| 24338-0855-03 | 30 TABLET in 1 BOTTLE (24338-855-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
| 24338-0856-03 | 30 TABLET in 1 BOTTLE (24338-856-03) | Zenzedi | Azurity Pharmaceuticals, Inc. | 2021-03-12 |
Observed labelers:
Azurity Pharmaceuticals, Inc. (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.